Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ESMO Breast 2021 | ESMO Breast 2021 highlights

Sung-Bae Kim • 4 May 2021

ESMO Breast 2021

Breast Cancer

Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, discusses the highlights of the ESMO Breast 2021 virtual congress. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

How can we move beyond endocrine therapy in HR+/HER2- breast cancer?

How can we move beyond endocrine therapy in HR+/HER2- breast cancer?

Sung-Bae Kim • 18 Dec 2025

TROPION-Breast02: first-line datopotamab deruxtecan in metastatic TNBC

TROPION-Breast02: first-line datopotamab deruxtecan in metastatic TNBC

Sung-Bae Kim • 18 Dec 2025

OPTIMAL: oral vs IV paclitaxel in HER2-negative, chemo-naive metastatic breast cancer

OPTIMAL: oral vs IV paclitaxel in HER2-negative, chemo-naive metastatic breast cancer

Sung-Bae Kim • 30 May 2025

EMBER-3: East Asian subgroup analysis of imlunestrant and abemaciclib

EMBER-3: East Asian subgroup analysis of imlunestrant and abemaciclib

Sung-Bae Kim • 28 May 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?

How will SARMs fit into the current breast cancer treatment paradigm?

Rafael Grochot • 2 Jul 2026

Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer

Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer

Rafael Grochot • 2 Jul 2026

$HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?$

HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?

Sanjoy Chatterjee • 17 May 2026

Design and aim of the HYPORT study in regional nodal breast cancer

Design and aim of the HYPORT study in regional nodal breast cancer

Sanjoy Chatterjee • 17 May 2026